Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Favre revealed his diagnosis with Parkinson's disease. Now, he's working to find treatment solutions. Favre joined Ambio Life ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...

Scientists from the University of Rochester and other institutions have uncovered new evidence that exposure to ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion therapy, a cutting-edge ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.